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Background: Adaptive servo-ventilation (ASV) can improve ventilatory inefﬁciency and exercise oscillatory ven-
tilation (EOV) in patients with heart failure (HF) and central sleep apnea (CSA). Although these improvements
might originate from both increase in cardiac function and decrease in sympathetic nerve activity, mechanisms
underlying the interrelationship remain unknown.
Methods:We compared cardiopulmonary exercise test, muscle sympathetic nerve activity (MSNA) and echocar-
diography ﬁndings at baseline and 3.5 ± 0.8 months (mean ± SD) of follow-up in 28 patients with both HF
(New York Heart Association functional class II and III; left ventricular ejection fraction (LVEF) b45%) and CSA
(apnea–hypopnea index (AHI) ≥15/h). Of these, 17 patients consented (ASV group) and 11 patients declined
(non-ASV group) to undergo ASV treatment. Compliance with ASV and changes in AHI were determined from
data collected by integral counters.
Results: VE/VCO2-slope and EOV amplitude at baseline were positively correlatedwith MSNA, but not with LVEF.
ASV therapy reduced VE/VCO2-slope and EOV amplitude (both p b 0.01) in association with decrease in MSNA
(p b 0.01) and increase in LVEF (p b 0.001). In non-ASV group, however, these parameters remained unchanged.
Change in VE/VCO2-slope was correlated with both change in AHI and average use of ASV. By contrast, change in
EOV amplitude was correlatedwith change in AHI. Changes in VE/VCO2-slope and EOV amplitude were correlat-
ed with changes of MSNA (p b 0.05), but not with those in LVEF.
Conclusions: ASV improves ventilatory inefﬁciency and EOV probably via suppression of CSA and its
sympathoinhibitory effect.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Patients with heart failure (HF) frequently have both central sleep
apnea (CSA) and obstructive sleep apnea during asleep [1,2]. Sleep
apnea causes repetitive episodes of hypoxia and arousal from sleep,
thereby activating the sympathetic nervous system to result in a predis-
position to arrhythmias; thus sleep apnea might comprise an indepen-
dent risk factor for major cardiac events [3–5].
In patients with CSA, several respiratory abnormalities during
cardiopulmonary exercise test have been identiﬁed. Ventilatory efﬁ-
ciency during exercise is impaired in HF patients with CSA comparedternal Medicine, University of
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land Ltd. Open access under CC BY-NCwith those without CSA [6]. Nocturnal continuous positive airway
pressure alleviated CSA and improved ventilatory inefﬁciency [7].
Exercise oscillatory ventilation (EOV) is known as a slowly and consis-
tently ﬂuctuating ventilation throughout the entire period of exercise
test, or disappearing during early exercise, or only disappearing at
peak exercise [8,9]. Similar to CSA, ventilatory inefﬁciency or EOV is
also an independent predictor of poor outcome in patients with HF
[10,11].
Adaptive servo-ventilation (ASV), which can almost eliminate CSA
and normalize breathing, has recently become applicable to patients
with HF accompanied by CSA [12]. ASV can improve cardiac function,
EOV, ventilatory inefﬁciency and hypercapnic chemosensitivity in
patients with HF and CSA [13–16]. However, mechanisms underlying
these improvements remain unknown. It has been shown that
sympathoexcitation relates to increased chemosensitivity and venti-
latory inefﬁciency in patients with HF [17–19]. We also showed that
ASV decreased sympathetic nerve activity measured directly as muscle
sympathetic nerve activity (MSNA) in association with suppression of
CSA in patients with HF [20]. Therefore, the present study aimed to in-
vestigate whether ASV improved EOV and ventilatory efﬁciency and, if
so, to elucidate the underlying mechanisms. We hypothesized that
treating CSA with ASV would improve EOV and ventilatory inefﬁciency
through effects on cardiac function and sympathetic nerve activity.-ND license.
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2.1. Study protocol
The present study included 40 patients with stable HF (New York
Heart Association functional classes II and III, left ventricular ejection
fraction (LVEF) b45%, a ﬁrst HF diagnosed at least six months be-
fore enrolment), treatment according to current guidelines for
≥3 months and sleep-disordered breathing (apnea–hypopnea
index (AHI) ≥15/h) with dominant central apnea and hypopnea
(Fig. 1). The etiology of heart disease was ischemic (n = 12) and
non-ischemic (n = 28). Patients with pacemakers, deﬁbrillators,
or resynchronization devices were included if the device had
been implanted for more than six months. Patients with primary
valvular heart diseases were excluded. Patients with stroke, respi-
ratory failure or pulmonary disease, severe anemia and end-stage
renal disease treated by hemodialysis were also excluded from
the study.
Cardiopulmonary exercise test and MSNA including measurements
of neurohumoral factors were analyzed at baseline. However, seven
of 40 patients disagreed to participate in the follow-up study. There-
fore, the remaining 33 patients underwent an ASV test. Twenty of
them agreed to continue with ASV, but the remaining 13 declined
during mask ﬁtting or daytime ASV testing. Repeated cardiopulmo-
nary exercise test was refused by 1 of 20 patients who accepted
ASV treatment and 1 of 13 patients who declined ASV treatment.
Microneurography results were not of sufﬁcient quality for 2 of 20
patientswho accepted ASV treatment and 1 of 13 patientswho declined
ASV treatment during the follow-up (Fig. 1). All patients were followed
upmonthly in our outpatient clinic. Measurements of cardiorespiratory
polygraphy, cardiopulmonary exercise test, humoral factors, and 2-
dimensional echocardiography and microneurography were also per-
formed at 3.5 ± 0.8 months (mean ± SD) of follow-up in 28 patients
who consented (n = 17; ASV group) or declined (n = 11; non-ASV
group) to undergo ASV treatment. The Institutional Ethics Board of To-
yama University Hospital approved the study protocol, which complied
with the Declaration of Helsinki. Written informed consent was obtain-
ed from all patients.Fig. 1. Flow chart of study population. ASV, adaptive servo-ventilation; CPET, cardiopulmonary
activity; NYHA, New York Heart Association.2.2. Sleep study
The patients were monitored using a cardiorespiratory monitoring
device (Somté, Compumedics, Abbotsford, Australia) to determine pro-
portion of CSA and obstructive sleep apnea during sleep [21]. Electrocar-
diographic recordings, nasal airﬂow (nasal pressure), thoracic and
abdominal effort, arterial oxygen saturation, pulse rate and body posi-
tion were analyzed. Thoracoabdominal movements were recorded by
respiratory inductance plethysmography, and oxyhemoglobin satura-
tion was monitored using ﬁnger pulse oximetry.
Respiratory events (CSA, obstructive sleep apnea, and mixed
apnea and hypopnea) were detected and oximetry ﬁndings were vi-
sually evaluated. The oxygen desaturation index was deﬁned as
number of instances per hour of total recording in which oxyhemo-
globin saturation fell by ≥4%. Apnea was deﬁned as complete cessa-
tion of air ﬂow for N10 s, and hypopnea as N50% attenuation of air
ﬂow accompanied by a reduction in SpO2 of≥4%. AHI was calculated
for each patient as the mean number of apneic and hypopneic events
per hour of the recording. The central and obstructive apnea indices
were calculated as the mean number of central and obstructive ap-
neic events, respectively.
2.3. Cardiopulmonary exercise test
Each subject was evaluated at least 2 h after a meal [18]. Patients
were asked to perform progressive maximal symptom-limited exercise
while seated upright on an electronically braked cycle ergometer
(Aerobike 75XL, Combi, Tokyo, Japan). Initially, patients performed
unloaded cycling for 3 min. Then, the work rate was increased progres-
sively by 5 to 10watts everyminute. Thework rate incrementwas indi-
vidualized on the basis of the subject's exercise capacity. Every subject
terminated the exercise because of leg fatigue or dyspnea. Heart rate
was monitored together with blood pressure, which was measured by
the cuff method at 1-min intervals throughout the test. Oxygen uptake
(VO2), carbon dioxide production (VCO2), minute ventilation (VE),
tidal volume, and respiratory rate were continuously measured on
breath by breath basis using a metabolic measurement cart equipped
with an oxygen and carbon dioxide analyzer (Minato AE-300, Osaka,exercise test, CSA, central sleep apnea; HF, heart failure; MSNA, muscle sympathetic nerve
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nique. Exercise tolerance was evaluated using the peak VO2. In the
present study, the exercise ventilatory response was assessed by
the regression slope between VE and the corresponding VCO2 below
the level of respiratory compensation required for metabolic acidosis
(VE/VCO2). In all subjects, VE correlated with VCO2 in a highly linear
fashion.
Cycles of oscillatory ventilation were displayed on an expanded
time scale for VE, VO2, and VCO2. EOV was assessed with the criteria
previously reported by Leite et al. [22]. Speciﬁcally, EOV was deﬁned
according to the following criteria: 1) 3 or more regular oscillatory
ﬂuctuations in VE; 2) minimal average amplitude of ventilatory oscilla-
tion of 5 l/min (peak value — the average of 2 in-between cosecutive
nadirs); and 3) a regular oscillation as deﬁned by an standard deviation
of 3 consecutive cycle lengths (time between 2 consecutive nadirs)
within 20% of the average. The cycle length of oscillation was deﬁned
as the period of observed oscillation divided by the number of
oscillation.2.4. Echocardiography
LVEF and left atrial dimension were determined using 2-dimensional
echocardiography (Aplio SSA-770A, Toshiba, Tokyo, Japan). The left
ventricular end-diastolic and end-systolic volumes were determined
according to a modiﬁcation of Simpson's method. LVEF was calculat-
ed as stroke volume (end-diastolic volume minus end-systolic vol-
ume) divided by end-diastolic volume.2.5. Measurement of heart rate, blood pressure, respiration and muscle
sympathetic nerve activity
All parameters were measured at rest while awake in the supine
position as described elsewhere [23,24]. Brieﬂy, blood pressure was
serially recorded using noninvasive tonometry (Jentow 7700, Colin,
Komaki, Japan). Multiunit recordings of efferent postganglionic sym-
pathetic nerve activity to skeletal muscle regions were obtained via a
microelectrode inserted directly into the left peroneal nerve posterior
to the ﬁbular head [23,24]. The nerve signal was ampliﬁed × 100,000,
passed through a band-pass ﬁlter (500 – 5000 Hz), and integrated
with a custom nerve-trafﬁc analysis system (NeuropackΣMEB-5504,
Nihon Kohden, Tokyo, Japan). Blood samples were withdrawn from
the antecubital veins to measure levels of brain natriuretic peptide
(BNP) and norepinephrine.
Data were analyzed in a blinded manner by two of the investigators
(RU and YO). MSNA is expressed as burst rate (bursts/min) and inci-
dence (bursts/100 beats). Respiratory patterns were continuously
monitored as thoracic electrical impedance. We conﬁrmed the corre-
lation between lung volumes and the amplitude of respiratory sig-
nals from electrical impedance as described previously [24]. We
also evaluated the prevalence of periodic breathing during MSNA re-
cording as described because it could inﬂuence MSNA [24].2.6. Effect of adaptive servo-ventilation
Regular follow-up visits (1/month) were scheduled in all patients.
Therapywas initiated using theAutoSet CS device (AutoSet CS; ResMed,
Sydney, Australia) and full face masks (Ultra MirageTM; ResMed,
Australia). It consisted of expiratory positive airway pressure at
4 – 5 cmH2O and a suitable minimum –maximum inspiratory sup-
port, which fell in the recommended setting range of 3 – 10 cmH2O. The
ASV device stored compliance and efﬁcacy data, which were
downloaded and analyzed using Res-ScanTM software (ResMed, Syd-
ney, Australia). The data recorded included days, hours, and minutes
the device was used, AHI, and apnea index.2.7. Deﬁnition of average use of ASV and change in AHI
Using the duration (hours) of ASV in the treatment period (days)
assessed by the integral device counters, the average use of ASV
(h/day) could be assessed for each participant as:
Hours of sleep during total treatment period with ASV
Total treatment period daysð Þ
Because ASV consistently reduces AHI [13], changes in the AHI of
patients who used ASV or not were calculated as:
AHI follow−up with ASVð Þ−AHI baselineð Þ
and
AHI follow−up without ASVð Þ−AHI baselineð Þ;
respectively [20].
2.8. Statistical analysis
Data are expressed as mean ± standard deviation. Analyses were
performed using statistical software (SigmaPlot version 11.2, SPSS inc.,
Chicago, Illinois). Variables between groups were compared using an
unpaired t-test, paired t-test, the Mann–Whitney U-test or the χ2 test.
Differences in MSNA and other clinical parameters between two study
periods were analyzed using the two-way analysis of variance for
repeated measures and the Bonferroni procedure was used for mul-
tiple comparisons. Relationships between change in VE/VCO2-slope
and clinical parameters were analyzed using linear regression analy-
sis. Parameters with statistical signiﬁcance in the univariate analysis
were included in themultivariate analysis. The level of statistical sig-
niﬁcance was set at p b 0.05.
3. Results
Table 1 summarizes demographic and clinical characteristics of the
patients. The groups did not differ regarding age, body mass index, eti-
ology of HF, heart rhythm, medications, New York Heart Association
functional class, and parameters of sleep-disordered breathing and
cardiopulmonary exercise test. In 40 patients with moderate to severe
CSA (AHI 26 ± 13/h, central apnea index 16 ± 11/h), EOV was con-
ﬁrmed in 16 patients and was not in 24. Patients with EOV had higher
VE/VCO2-slope, norepinephrine level and burst rate than those without
EOV did. However, peak VO2, BNP level and LVEF were comparable be-
tween the 2 groups.
3.1. Effect of ASV on clinical parameters in HF patients with CSA
Both AHI and central apnea index signiﬁcantly decreased (p b 0.001),
whereas minimum oxygen saturation increased (p b 0.001) from base-
line to follow-up in the ASV group (Table 2), but not in the non-ASV
group. The average daily use of ASV and the number of days ASV was
used divided by the total number of days studied were 4.4 ± 1.9 h/day
and 85 ± 26%, respectively in the ASV group. The AHI determined in
the ASV group using integral device counters and polygraphy were
quite similar, i.e., 3 ± 3 and 2 ± 3 events/h, respectively.
The speciﬁc activity scale improved in the ASV, but not in the non-
ASV group (Table 2). Levels of BNP level signiﬁcantly decreased and
LVEF increased in the ASV, but not in the non-ASV group (p b 0.001).
Microneurographic variables were similar on two occasions in the
non-ASV group (Table 2). Although blood pressure did not change,
burst rate, burst incidence and the prevalence of periodic breathing
were signiﬁcantly decreased in the ASV group (Table 2). Similarly,
plasma norepinephrine level reduced signiﬁcantly in the ASV group,
but did not change in the non-ASV group.
Table 1
Comparison in ASV and non-ASV groups.
Parameters All patients
(n = 40)
Patients studied twice
(n = 28)
Non-ASV group
(n = 11)
ASV group
(n = 17)
p-value
non-ASV vs ASV
Age (years) 62 ± 10 64 ± 10 68 ± 8 61 ± 11 0.09
Gender (male, %) 90% 96% 100% 94% 0.43
Ischemic cause of heart failure (%) 30% 36% 45% 29% 0.41
NYHA (class) 2.4 ± 0.6 2.5 ± 0.5 2.6 ± 0.5 2.4 ± 0.5 0.26
Body mass index (kg/m2) 24.0 ± 3.4 24.0 ± 3.3 24.3 ± 3.2 23.9 ± 3.5 0.75
Rhythm (%)
t 0.98Sinus rhythm 55 50 55 47Atrial ﬁbrillation 35 36 36 35
Pacemaker 5 7 0 12
CRT 5 7 9 6
LVEF (%) 32 ± 9 31 ± 9 32 ± 9 30 ± 9 0.54
LVDd (mm) 66 ± 10 66 ± 10 66 ± 10 65 ± 10 0.82
Peak VO2 (ml/kg/min) 15.0 ± 3.7 14.2 ± 3.1 13.5 ± 2.1 14.6 ± 3.5 0.35
VE/VCO2-slope 0.035 ± 0.007 0.036 ± 0.008 0.036 ± 0.006 0.036 ± 0.009 0.94
EOV (%) 40 54 55 53 0.94
EOV amplitude (l/min) 5.1 ± 4.6 5.3 ± 4.1 4.8 ± 4.2 5.7 ± 4.1 0.55
BNP (pg/ml) 281 ± 244 326 ± 285 256 ± 226 371 ± 316 0.31
Norepinephrine (pg/ml) 393 ± 237 417 ± 253 389 ± 203 435 ± 286 0.64
MSNA Burst rate (/min) 51 ± 16 53 ± 14 54 ± 13 52 ± 14 0.78
MSNA Burst incidence (/100beats) 73 ± 18 75 ± 16 78 ± 14 72 ± 17 0.33
AHI (events/h) 26 ± 13 25 ± 13 22 ± 7 27 ± 15 0.34
CAI (events/h) 16 ± 11 15 ± 10 14 ± 8 16 ± 12 0.61
Medications (%)
RAS inhibitors 100 100 100 100 -
β-blockers 85 82 73 88 0.31
Loop diuretics 73 79 73 82 0.56
Mineralcorticoid receptor antagonists 50 46 45 47 0.94
Statins 38 50 55 47 0.71
Digitalis 25 25 27 24 0.83
pH 7.43 ± 0.03 7.43 ± 0.03 7.43 ± 0.02 7.43 ± 0.03 0.96
pO2 (torr) 88 ± 9 87 ± 9 83 ± 8 89 ± 9 0.07
pCO2 (torr) 38 ± 5 38 ± 5 38 ± 5 37 ± 5 0.73
Values are means ± SD or ratio (%) of patients. AHI, apnea–hypopnea index; ASV, adaptive servo-ventilation; BNP, brain natriuretic peptide; CAI, central apnea index; CRT, cardiac
resynchronization therapy; EOV, exercise oscillatory ventilation; LVDd, left ventricular diastolic dimension; LVEF, left ventricular ejection fraction; MSNA, muscle sympathetic nerve ac-
tivity; NYHA, New York Heart Association; RAS, renin–angiotensin system; VCO2, carbon dioxide production; VE, minute ventilation; VO2, oxygen consumption.
Table 2
Effect of ASV on sleep parameters, cardiac function, hemodynamics and neurohumoral factors.
Parameters Non-ASV group (n = 11) ASV group (n = 17)
Baseline Follow-up p-value Baseline Follow-up(During ASV) p-value Interaction
Sleep characteristics
AHI (events/h) 22 ± 7 23 ± 12 NS 27 ± 15 2 ± 3 b0.001 b0.001
CAI (events/h) 14 ± 8 13 ± 13 NS 16 ± 12 0 ± 1 b0.001 b0.01
OAI (events/h) 2 ± 1 1 ± 1 NS 2 ± 4 0 ± 0 b0.05 NS
MAI (events/h) 1 ± 1 1 ± 1 NS 1 ± 1 0 ± 0 b0.01 b0.01
Hypopnea index (events/h) 6 ± 3 8 ± 7 NS 8 ± 7 2 ± 2 b0.001 b0.01
Mean oxygen saturation (%) 96 ± 1 96 ± 1 NS 95 ± 1 97 ± 1 b0.01 b0.01
Minimal oxygen saturation (%) 86 ± 5 83 ± 6 NS 85 ± 4 89 ± 3 b0.01 b0.001
Speciﬁc activity scale (METs) 4.5 ± 1.3 4.8 ± 1.2 NS 4.5 ± 1.2 5.5 ± 1.3 b0.001 NS
Echocardiography
LVEF (%) 32 ± 9 31 ± 9 NS 30 ± 9 37 ± 12 b0.001 b0.01
LVDd (mm) 66 ± 10 65 ± 12 NS 65 ± 10 62 ± 11 b0.01 NS
LVDs (mm) 55 ± 11 55 ± 13 NS 56 ± 11 51 ± 14 b0.001 b0.05
LAD (mm) 46 ± 4 48 ± 9 NS 50 ± 9 46 ± 9 b0.05 b0.05
TTPG (mm Hg) 24 ± 14 33 ± 18 NS 27 ± 13 20 ± 11 NS NS
Neurohumoral factors
HR (beats/min) 67 ± 15 70 ± 7 NS 75 ± 14 68 ± 13 NS NS
SBP (mm Hg) 116 ± 19 115 ± 16 NS 109 ± 14 109 ± 13 NS NS
DBP (mm Hg) 66 ± 11 63 ± 11 NS 61 ± 11 60 ± 7 NS NS
SpO2 (%) 97 ± 2 97 ± 2 NS 97 ± 1 97 ± 2 NS NS
Periodic breathing (%) 55 82 NS 59 29 b0.05 b0.05
Burst rate (bursts/min) 54 ± 13 50 ± 15 NS 52 ± 14 39 ± 14 b0.001 NS
Burst incidence (bursts/100 beats) 78 ± 14 78 ± 19 NS 72 ± 17 62 ± 16 b0.01 NS
Norepinephrine (pg/ml) 389 ± 203 374 ± 172 NS 435 ± 286 322 ± 186 NS NS
BNP (pg/ml) 256 ± 226 378 ± 270 NS 371 ± 316 185 ± 168 b0.01 b0.01
Values are means ± SD. AHI, apnea–hypopnea index; ASV, adaptive servo-ventilation; BNP, brain natriuretic peptide; CAI, central apnea index; DBP, diastolic blood pressure; HR, heart
rate; LAD, left atrial dimension; LVDd, left ventricular diastolic dimension; LVDs, left ventricular systolic dimension; LVEF, left ventricular ejection fraction; MAI, mixed apnea index;
MSNA, muscle sympathetic nerve activity; OAI, obstructive apnea index; SBP, systolic blood pressure; SpO2, oxygen saturation; TTPG, trans-tricuspid pressure gradient.
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Table 3
Effect of ASV on parameters of cardiopulmonary exercise test.
Parameters Non-ASV group (n = 11) ASV group (n = 17)
Baseline Follow-up p-value Baseline Follow-up p-value Interaction
Peak load (watts) 65 ± 18 70 ± 21 NS 75 ± 25 91 ± 31 b0.001 NS
Peak VO2 (ml/kg/min) 13.5 ± 2.1 14.0 ± 2.9 NS 14.6 ± 3.5 17.4 ± 4.3 b0.001 b0.05
O2 pulse (ml/beat/kg/100) 8.1 ± 1.8 8.4 ± 2.1 NS 7.8 ± 2.2 9.5 ± 2.5 b0.001 b0.05
VE/VCO2-slope 0.036 ± 0.006 0.036 ± 0.005 NS 0.036 ± 0.006 0.031 ± 0.006 b0.001 b0.05
EOV cycle length (s) 62 ± 39 63 ± 35 NS 81 ± 35 65 ± 25 NS NS
Values are means ± SD. ASV, adaptive servo-ventilation; EOV, exercise oscillatory ventilation; VCO2, carbon dioxide production, VE, minute ventilation; VO2, oxygen uptake.
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but they did not change in the non-ASV group (Table 3, Fig. 2). Addition-
ally, amplitude of EOV also decreased signiﬁcantly in the ASV group
(Fig. 2). Peak VO2 increased in the ASV group (both p b 0.001), but
not in the non-ASV group (Table 3).
3.2. Univariate analysis
VE/VCO2-slope at baseline was signiﬁcantly correlated with burst
rate (p b 0.001, Fig. 3), burst incidence (p = 0.003) and plasma norepi-
nephrine level (p b 0.001), but notwith LVEF. Thiswas also true for EOV
amplitude at baseline (Fig. 3). Moreover, change in VE/VCO2-slope was
correlated with changes in burst rate, burst incidence and plasma nor-
epinephrine level, but not with change in LVEF (Table 4). This was
also true for change in EOV amplitude (Table 4).
Importantly, the change in AHI correlated with changes in VE/VCO2-
slope and EOV amplitude. By contrast, the average use of ASV correlated
with changes in VE/VCO2-slope, but not with those in EOV amplitude.
4. Discussion
The major ﬁndings of the present study are as follows: 1) Patients
with EOV had higher VE/VCO2-slope, norepinephrine level and burst
rate than those without EOV did. 2) ASV increased LVEF and peak VO2
accompanied by a decrease inVE/VCO2-slope, amplitude of EOV, plasma
norepinephrine level and MSNA. 3) Changes of VE/VCO2-slope and
amplitude of EOVwere correlated with changes of MSNA and norepi-
nephrine level, but not with changes in LVEF. 4) Changes of VE/VCO2-
slope and amplitude of EOVwere correlatedwith changes of AHI. TheseFig. 2. Prevalence and amplitude of exercise oscillatory ventilation (EOV). Both prevalence
of EOV and amplitude of EOV decreased in the ASV group, but they did not change in the
non-ASV group. Open circle = ASV group; Solid square = non-ASV group.ﬁndings indicated that ASV improved exercise tolerance and ventilatory
inefﬁciency in patients with HF and CSA. These beneﬁcial effects of ASV
might be via suppression of CSA and its sympathoinhibitory effect.
4.1. Effect of ASV on ventilatory efﬁciency
It has been shown that ASV could improve ventilatory inefﬁciency in
patients with HF [14]. Although exact mechanisms of the improvement
using ASV remain unknown, several mechanisms might relate to the
improvement. First, long-term hemodynamic effects of ASV would
lead to improvement in cardiac function and exercise-associated hemo-
dynamic responses. Improvement of hemodynamics and pulmonary
dead space might be related to improvement of ventilatory efﬁciency
[25,26]. In fact, LVEF and BNP level improved signiﬁcantly after the
use of ASV in the present study. However, we found that there was no
signiﬁcant correlation between change in VE/VCO2-slope and that in
LVEF. Second, sympathoinhibitory effect of ASVmight exert suppression
of hypercapnic chemosensitivity, thereby regulating ventilatory re-
sponse to exercise. Locus coeruleus as noradrenergic neurons was sug-
gested as a CO2 chemoreceptor site in mammals [27]. In animal model
with selective destruction of locus coeruleus noradrenergic neurons
by 6-hydroxydopamine, the hypercapnic ventilatory response was
signiﬁcantly decreased compared with sham operated animals [28].
Additionally, hypercapnic chemosensitivity and ventilatory inefﬁ-
ciency were closely correlated with plasma norepinephrine level or
MSNA in patients with HF [17–19]. Recently, we reported that ASV
reduced MSNA via abolition of CSA in HF patients with CSA [20]. In
the present study, we found that ASV reduced VE/VCO2-slope and
change in VE/VCO2-slope was signiﬁcantly correlated with that in
MSNA or plasma norepinephrine level. Therefore, sympathoinhibitory
effect by ASV might relate to improvement of ventilatory inefﬁciency.
4.2. Effect of ASV on EOV
So far, it has been shown that EOVmainly originates from two im-
portant mechanisms; 1) prolonged circulation time or low cardiac
output (metabo-hemodynamic hypothesis) and 2) increased hyper-
capnic chemosensitivity or hypocapnia resulting from the increased
chemosensitivity (ventilatory hypothesis) [29]. Although the exact
mechanisms of abolition of EOV using ASV remain unknown, improve-
ment of above mechanisms might relate to respiratory stabilization
during exercise. First, increased cardiac function by ASV might relate
to abolition of EOV. However, there was no signiﬁcant relationship be-
tween change in LVEF and change in EOV amplitude in the present
study. Second, sympathoinhibitory effect by ASV might relate to aboli-
tion of EOV. Supporting this mechanism is that changes in MSNA or
plasma norepinephrine level were signiﬁcantly correlated with change
of EOV amplitude. Third, abolition of EOV by ASV might be attributable
to reduction of pulmonary arterial pressure. Recently, it has been shown
that sildenaﬁl, a phosphodiesterase 5 inhibitor, can reverse EOV in pa-
tients with HF. Notably, the correction of EOV was closely correlated
with changes in pulmonary arterial pressure and pulmonary vascular
resistance [30]. In the present study, we showed that prevalence and
Fig. 3.Relationship betweenmuscle sympathetic nerve activity (burst rate) andVE/VCO2 slope or amplitude of exercise oscillatory ventilation (EOV). VE/VCO2-slope and amplitude of EOV
at baseline were positively correlated with burst rate.
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previousﬁnding revealed thatASV reduced pulmonary arterial pressure
in HF patients with CSA [20]. However, there was no relationship be-
tween change in transtricuspid pressure gradient and change of EOV
amplitude in the present study. Thus, sympathoinhibition rather than
improvement of cardiac function might be related to improvement of
EOV.4.3. Limitations
The present study had several limitations. Firstly, the sample size
was small, so that the statistical analyses might be insufﬁcient to
draw a deﬁnite conclusion. In addition, it was not a randomized
study and non-ASV group consisted of patients that did not tolerate
the ASV therapy. A larger sample size or randomized study is required
to draw unambiguous conclusions. Secondly, we did not measure
chemosensitivity to hypercapnia or hypoxia. Therefore, the question
whether EOV origin is “central” or “peripheral” is still unanswered.
Thirdly, we did not use polysomnography. Therefore, the present re-
sults would not be the same as those determined by polysomnography.
Fourthly, we adopted Leite's criteria to deﬁne EOV. However, another
one, Corra's criteria, was also used for detection of EOV in the previous
study [31]. Recent study demonstrated that the prevalence of EOV de-
termined by both criteria were very similar (Corra 25 %, Leite 31%)
[32]. Therefore, the result might be not quite different irrespective ofTable 4
Correlation between use or beneﬁcial effect of ASV and parameters of cardiopulmonary
exercise test.
ΔVE/VCO2-slope ΔEOV amplitude Δpeak VO2
R p value R p value R p value
ΔAHI (events/h) 0.432 0.022 0.63 b0.001 -0.613 b0.001
Average use (h) -0.391 0.04 -0.199 0.311 0.483 0.009
ΔBurst rate 0.398 0.036 0.316 0.101 -0.363 0.058
ΔBurst incidence 0.520 0.005 0.405 0.032 -0.279 0.15
ΔNorepinephrine 0.512 0.005 0.482 0.009 -0.342 0.075
ΔBNP 0.387 0.042 0.432 0.021 -0.377 0.048
ΔLVEF -0.520 0.003 -0.327 0.089 0.359 0.061
AHI, apnea–hypopnea index; ASV, adaptive servo-ventilation; BNP, brain natriuretic pep-
tide; EOV, exercise oscillatory ventilation; LVEF. left ventricular ejection fraction; VE/VCO2,
minute ventilation to carbon dioxide production, VO2, oxygen consumption.used criteria of EOV. Lastly, clinical characteristics and medications
were similar between the ASV and non-ASV groups, but refusing the
proffered therapy of ASV might indicate nonadherence to other thera-
pies, including medication. However, one study found that medication
adherence and persistence are not associated with adherence to posi-
tive airway pressure therapy [33].
Although limited for these reasons, the present ﬁndings suggest that
ASV improves EOV and ventilatory efﬁciency through effects of ASV on
sympathetic nerve activity. Further study might warrant to recognize
exact mechanisms of such beneﬁcial effects.
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